Jefferies Group LLC Macrogenics Inc Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $117,389 - $203,580	39,000 New	39,000 $12,000
Q3 2020 Nov 13, 2020	SELL	$24.69 - $31.6 $48,417 - $61,967	-1,961 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $10,197 - $57,104	1,961 New	1,961 $55,000
Q1 2020 May 15, 2020	SELL	$4.28 - $12.11 $48,488 - $137,194	-11,329 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$7.95 - $12.27 $160,844 - $248,246	-20,232 Reduced 64.1%	11,329 $123,000
Q3 2019 Nov 13, 2019	BUY	$12.44 - $17.48 $376,446 - $528,962	30,261 Added 2327.77%	31,561 $403,000
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $113,178 - $153,738	-7,800 Reduced 85.71%	1,300 $22,000
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $101,101 - $232,960	9,100 New	9,100 $164,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.